Upregulation of Proinflammatory Bradykinin Peptides in Systemic Lupus Erythematosus and Rheumatoid Arthritis

Abstract

Our recent study has implicated bradykinin (BK) signaling as being of pathogenic importance in lupus. This study aims to investigate the biomarker potential of BK peptides, BK and BK-des-arg-9, in lupus and other rheumatic autoimmune diseases. Sera from systemic lupus erythematosus (SLE) patients and healthy subjects were screened for BK and BK-des-arg-9 by liquid chromatography-mass spectrometry metabolomics. Serum from 6-mo-old C57BL/6 mice and three murine lupus strains were also screened for the two peptides by metabolomics. Given the promising initial screening results, validation of these two peptides was next conducted using multiple reaction monitoring in larger patient cohorts. In initial metabolomics screening, BK-des-arg-9 was 22-fold higher in SLE serum and 106-fold higher in mouse lupus serum compared with healthy controls. In validation assays using multiple reaction monitoring and quadrupole time-of-flight mass spectrometry, BK and BK-des-arg-9 showed significant elevations in SLE serum compared with controls (p < 0.0001; area under the curve = 0.79-0.88), with a similar but less pronounced increase being noted in rheumatoid arthritis serum. Interestingly, increased renal SLE disease activity index in lupus patients was associated with reduced circulating BK-des-arg-9, and the reasons for this remain to be explored. To sum, increased conversion of BK to the proinflammatory metabolite BK-des-arg-9 appears to be a common theme in systemic rheumatic diseases. Besides serving as an early marker for systemic autoimmunity, independent studies also show that this metabolic axis may also be a pathogenic driver and therapeutic target in lupus.

The contact activation system and vascular factors as alternative targets for Alzheimer's disease therapy

“…61,109,110 Therefore, blocking the contact system in patients would not increase the risk of hemorrhage. The 3E8 anti-HK antibody or other contact system inhibitors could be effective at ameliorating not only vascular and inflammatory pathologies in AD but also other diseases and vascular pathologies in which the contact system is also dysregulated, such as hereditary angioedema, 111 sickle cell anemia, 112 lupus, 113 rheumatoid arthritis, 114 multiple sclerosis-associated neuroinflammation, 66,115 infection (sepsis/endotoxemia), 116,117 and colitis. 118…”

Discovery and Functional Characterization of Two Regulatory Variants Underlying Lupus Susceptibility at 2p13.1

“…We next performed a search for non-miRNA targets of DGUOK-AS1 ( Table S4 ). The top hits included the inflammatory peptide bradykinin, which is upregulated in SLE, rheumatoid arthritis, and Hashimoto’s thyroiditis [ 33 ]; pattern recognition receptor 36, which is involved in the innate immune system [ 34 ]; and the lncRNA Xist , the principal mediator of X chromosome inactivation in females [ 35 ]— Xist has been shown to strongly contribute to B-cell modulation and sex bias in SLE and arthritis [ 36 ].…”

Evidence From Fatal Covid-19 for Targeting the Bradykinin Metabolism—a Single-Center Cohort Study

“…Interestingly, elevated DABK levels have also been found in sera from systemic lupus erythematosus and rheumatoid arthritis patients (33), indicating a chronic systemic inflammatory involvement of DABK. Furthermore, the same authors previously demonstrated that blocking the B 1 R ameliorates murine lupus nephritis, suggesting that elevated DABK levels drive inflammation by engaging the B 1 R in systemic lupus erythematosus (34).…”